Malignant melanoma

Current state of primary and adjuvant treatment

Timothy M. Pawlik, Vernon K. Sondak

Research output: Contribution to journalArticle

Abstract

Metastatic malignant melanoma remains a highly lethal disease with an incidence that continues to rise. Management of melanoma includes definitive local, regional and distant control. There is substantial prospective and retrospective data to base the extent of both primary as well as adjuvant therapy. The results of these trials have on occasion been at odds. A critical assessment of the available information pertaining to the adjuvant treatment of cutaneous melanoma is needed. This review provides a critical assessment of the current data that is available to guide both primary resection as well as adjuvant therapy. To date, current trials have shown little promise with nonspecific immunostimulants and cytotoxic chemotherapy. In contrast, dose interferon-α2b has been shown to improve relapse-free survival and likely improves melanoma-specific survival as well. Based on the available data, interferon-α2b remains the adjuvant therapy of choice for high-risk patients treated outside clinical trials, and the appropriate control arm for clinical trials evaluating new or modified adjuvant regimens.

Original languageEnglish (US)
Pages (from-to)245-264
Number of pages20
JournalCritical Reviews in Oncology/Hematology
Volume45
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Melanoma
Interferons
Clinical Trials
Immunologic Adjuvants
Survival
Therapeutics
Recurrence
Drug Therapy
Skin
Incidence

Keywords

  • Adjuvant therapy
  • Interferon α
  • Melanoma
  • Sentinel node biopsy
  • Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Malignant melanoma : Current state of primary and adjuvant treatment. / Pawlik, Timothy M.; Sondak, Vernon K.

In: Critical Reviews in Oncology/Hematology, Vol. 45, No. 3, 01.03.2003, p. 245-264.

Research output: Contribution to journalArticle

Pawlik, Timothy M. ; Sondak, Vernon K. / Malignant melanoma : Current state of primary and adjuvant treatment. In: Critical Reviews in Oncology/Hematology. 2003 ; Vol. 45, No. 3. pp. 245-264.
@article{7c611d46f36d46d188196ee72f522020,
title = "Malignant melanoma: Current state of primary and adjuvant treatment",
abstract = "Metastatic malignant melanoma remains a highly lethal disease with an incidence that continues to rise. Management of melanoma includes definitive local, regional and distant control. There is substantial prospective and retrospective data to base the extent of both primary as well as adjuvant therapy. The results of these trials have on occasion been at odds. A critical assessment of the available information pertaining to the adjuvant treatment of cutaneous melanoma is needed. This review provides a critical assessment of the current data that is available to guide both primary resection as well as adjuvant therapy. To date, current trials have shown little promise with nonspecific immunostimulants and cytotoxic chemotherapy. In contrast, dose interferon-α2b has been shown to improve relapse-free survival and likely improves melanoma-specific survival as well. Based on the available data, interferon-α2b remains the adjuvant therapy of choice for high-risk patients treated outside clinical trials, and the appropriate control arm for clinical trials evaluating new or modified adjuvant regimens.",
keywords = "Adjuvant therapy, Interferon α, Melanoma, Sentinel node biopsy, Vaccines",
author = "Pawlik, {Timothy M.} and Sondak, {Vernon K.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1016/S1040-8428(02)00080-X",
language = "English (US)",
volume = "45",
pages = "245--264",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Malignant melanoma

T2 - Current state of primary and adjuvant treatment

AU - Pawlik, Timothy M.

AU - Sondak, Vernon K.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Metastatic malignant melanoma remains a highly lethal disease with an incidence that continues to rise. Management of melanoma includes definitive local, regional and distant control. There is substantial prospective and retrospective data to base the extent of both primary as well as adjuvant therapy. The results of these trials have on occasion been at odds. A critical assessment of the available information pertaining to the adjuvant treatment of cutaneous melanoma is needed. This review provides a critical assessment of the current data that is available to guide both primary resection as well as adjuvant therapy. To date, current trials have shown little promise with nonspecific immunostimulants and cytotoxic chemotherapy. In contrast, dose interferon-α2b has been shown to improve relapse-free survival and likely improves melanoma-specific survival as well. Based on the available data, interferon-α2b remains the adjuvant therapy of choice for high-risk patients treated outside clinical trials, and the appropriate control arm for clinical trials evaluating new or modified adjuvant regimens.

AB - Metastatic malignant melanoma remains a highly lethal disease with an incidence that continues to rise. Management of melanoma includes definitive local, regional and distant control. There is substantial prospective and retrospective data to base the extent of both primary as well as adjuvant therapy. The results of these trials have on occasion been at odds. A critical assessment of the available information pertaining to the adjuvant treatment of cutaneous melanoma is needed. This review provides a critical assessment of the current data that is available to guide both primary resection as well as adjuvant therapy. To date, current trials have shown little promise with nonspecific immunostimulants and cytotoxic chemotherapy. In contrast, dose interferon-α2b has been shown to improve relapse-free survival and likely improves melanoma-specific survival as well. Based on the available data, interferon-α2b remains the adjuvant therapy of choice for high-risk patients treated outside clinical trials, and the appropriate control arm for clinical trials evaluating new or modified adjuvant regimens.

KW - Adjuvant therapy

KW - Interferon α

KW - Melanoma

KW - Sentinel node biopsy

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=0037333374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037333374&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(02)00080-X

DO - 10.1016/S1040-8428(02)00080-X

M3 - Article

VL - 45

SP - 245

EP - 264

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -